Although FDA’s Device Center tends to exempt many Mobile Medical Apps from regualtion FDA’s Drug Center has its own approach. Our current understanding is that mobile apps distributed with drugs are considered part of a combination product in many cases and the Drug Center will review the MMApp information as part of the product approval process.